Second Sight Medical Products (EYES) Data Lures Option Bulls

Second Sight Medical Products Inc (EYES) is up on successful trial results

Digital Content Group
Apr 8, 2015 at 2:43 PM
facebook twitter linkedin

Second Sight Medical Products Inc (NASDAQ:EYES) is cruising higher this afternoon, following a successful trial of its Orion I Visual Cortical Prosthesis. Specifically, the shares are up 13.4% at $14.31 -- and options traders have taken notice.

Currently, intraday option volume for EYES is running at 21 times the usual rate, with calls nearly doubling puts on an absolute basis. The April 15 strike is attracting the most attention, with buy-to-open activity transpiring at both the call and put. By purchasing the out-of-the-money April 15 call, traders expect EYES will take out $15 by next Friday's close, when front-month options expire. Those purchasing the puts, however, anticipate the shares will reverse lower between now and then.

Technically speaking, Second Sight Medical Products Inc (NASDAQ:EYES) has put on quite the display in 2015. Today's upward gap brings the stock's year-to-date lead north of 39%, and above its 10- and 20-day moving averages, which have acted as resistance in recent weeks.

Daily Chart of EYES since March 2015 with 10-Day and 20-Day Moving Averages


If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

Schaeffer's Investment Research Master Portfolio Trial


Special Offers from Schaeffer's Trading Partners